<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000455147"><TermName>17-dimethylaminoethylamino-17-demethoxygeldanamycin</TermName><TermPronunciation>(17-dy-MEH-thul-uh-MEE-noh-EH-thul-uh-MEE-noh-17-dee-meh-THOK-see-gel-DA-nuh-MY-sin)</TermPronunciation><TermDefinition><DefinitionText>17-DMAG. A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called geldanamycin analogs.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000715227" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;17-dimethylaminoethylamino-17-demethoxygeldanamycin&quot;" language="en" id="_3"/><MediaLink ref="CDR0000715226" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;17-dimetilaminoetilamino-17-demetoxigeldanamicina&quot;" language="es" id="_4"/><SpanishTermName>17-dimetilaminoetilamino-17-demetoxigeldanamicina</SpanishTermName><SpanishTermDefinition><DefinitionText>17-DMAG. Sustancia en estudio para el tratamiento de cáncer. Pertenece a la familia de medicamentos que se llaman análogos de la geldanamicina.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2006-08-24</DateFirstPublished></GlossaryTerm>
